A bill for an act relating to the controlled substance crystalline polymorph psilocybin.
Summary
This bill creates a pathway in Iowa law for a specific pharmaceutical form of psilocybin, described as crystalline polymorph psilocybin and also referred to as COMP 360, to be removed from Schedule I if and when it is approved by the U.S. Food and Drug Administration. The bill ties Iowa’s treatment of the drug to federal action: once FDA approval occurs, the substance would be rescheduled according to FDA recommendations and its status under the federal Controlled Substances Act and related federal regulations.
The measure also provides that, after rescheduling, it would be lawful in Iowa to prescribe, distribute, and market the approved pharmaceutical composition under its approved trade name or any other FDA-approved name. In practical terms, the bill is aimed at creating state-law flexibility for a future psilocybin-based medicine, while preserving current restrictions until federal approval occurs.
Impact
The bill would amend Iowa Code section 124.201 governing controlled substances by adding a new subsection that carves out an FDA-approved crystalline polymorph psilocybin product from the state’s Schedule I classification upon federal approval. It would not change the current legal status of psilocybin generally before FDA approval, but it would require automatic state rescheduling of the specified pharmaceutical product once federal approval and scheduling changes occur. This would affect controlled-substance enforcement, prescribing authority, pharmacy distribution, and commercial marketing for the approved product, while leaving existing penalties for nonapproved psilocybin in place.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the overall sentiment appears cautious but supportive of a regulated medical pathway. The bill is framed as a narrow, future-oriented measure that follows federal approval rather than broadly liberalizing psilocybin policy. Its structure suggests an intent to align state law with federal drug approval processes and to avoid premature changes to current controlled-substance rules.
Contention
The main point of contention is likely to be the treatment of psilocybin, a substance currently classified as Schedule I and associated with hallucinogenic drug policy. Supporters would likely emphasize medical research, FDA oversight, and access to an approved treatment, while opponents may object to any step that normalizes a psilocybin-based product or worry about diversion, public health, and the implications of rescheduling a substance currently subject to serious criminal penalties. Because the bill only applies after FDA approval, another possible issue is whether state law should automatically follow federal scheduling decisions or retain independent state control.
Amending the definition of "psilocybin" in the uniform controlled substances act to exclude the pharmaceutical composition of crystalline polymorph psilocybin and adding crystalline polymorph psilocybin to schedule IV of the uniformed controlled substance act.
Reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.